311,157 results match your criteria Leukemia & Lymphoma[Journal]


Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia.

Support Care Cancer 2018 Dec 15. Epub 2018 Dec 15.

Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA.

Purpose: To investigate the impact of hyperglycemia and glycemic variability during intensive acute myeloid leukemia therapy (AML) on outcomes by age.

Methods: Retrospective study of 262 consecutive patients with newly diagnosed AML hospitalized for intensive induction. Hyperglycemia was assessed by mean blood glucose (BG) (mg/dL) during hospitalization and glycemic variability was determined by the standard deviation (SD) of mean BG. Read More

View Article
December 2018

Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents.

Bioorg Chem 2018 Dec 10;84:410-417. Epub 2018 Dec 10.

Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address:

HDAC inhibitors and BRD4 inhibitors were considered to be potent anti-cancer agents. Recent studies have demonstrated that HDAC and BRD4 participate in the regulation of some signal paths like PI3K-AKT. In this work, a series of indole derivatives that combine the inhibitory activities of BRD4 and HDAC into one molecule were designed and synthesized through the structure-based design method. Read More

View Article
December 2018

A prospective, multicentre study of involved-field radiotherapy with autologous stem cell transplantation for patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma (ALLG HDNHL04/TROG 03.03).

Int J Radiat Oncol Biol Phys 2018 Dec 13. Epub 2018 Dec 13.

Dept. Haematology, Westmead Hospital, Westmead, University of Sydney, NSW, Australia.

Purpose: The role of involved-field radiotherapy (IFRT) with autologous stem cell transplantation (ASCT) for lymphomas remains uncertain.

Methods: and materials; In this prospective, multicentre study, patients undergoing ASCT for relapsed/refractory lymphoma received peri-transplant IFRT to disease sites identified at study registration (SR) (before salvage chemotherapy (SC)). Radiation dose was adapted to SC response. Read More

View Article
December 2018

Smc3 is required for mouse embryonic and adult hematopoiesis.

Exp Hematol 2018 Dec 13. Epub 2018 Dec 13.

Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri. Electronic address:

SMC3 encodes a subunit of the cohesin complex that has canonical roles in regulating sister chromatids segregation during mitosis and meiosis. Recurrent heterozygous mutations in SMC3 have been reported in acute myeloid leukemia (AML) and other myeloid malignancies. In this study, we investigated whether the missense mutations in SMC3 might have dominant-negative effects or phenocopy loss-of-function effects by comparing the consequences of Smc3 deficient and haploinsufficient mouse models. Read More

View Article
December 2018

Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?

Blood Rev 2018 Dec 5. Epub 2018 Dec 5.

Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA. Electronic address:

Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an allogeneic hematopoietic stem cell transplant (HSCT) is proof of concept for the application of immunotherapy in AML and MDS. However, outside of HSCT, only the anti-CD33 antibody drug conjugate gemtuzumab ozogamicin is currently approved as an antibody-targeted therapy for AML. Read More

View Article
December 2018
1 Read

Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.

Cancer Genet 2018 Dec 27;228-229:41-46. Epub 2018 Aug 27.

Department of Hematopathology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009, USA. Electronic address:

Myeloproliferative neoplasms (MPN) associated with ABL1-ETV6 fusions are rare and poorly characterized. To date, less than 20 cases of ABL1-ETV6+ MPN have been reported. We report a 47-year-old man who presented with MPN with clinicopathologic features resembling chronic myeloid leukemia, but there was no evidence of t(9;22)(p34. Read More

View Article
December 2018
1 Read

A new complex rearrangement in infant ALL: t(X;11;17)(p11.2;q23;q12).

Cancer Genet 2018 Dec 28;228-229:110-114. Epub 2018 Oct 28.

Department of Pediatrics, Ribeirão Preto School of Medicine, University of São Paulo, Av. Bandeirantes 3900, Bairro Monte Alegre, Ribeirão Preto, SP CEP 14040-900, Brazil.

We present a case of an infant who developed pro-B acute lymphoblastic leukemia with a rare and complex MLL-translocation. Cytogenetic analysis of bone marrow cells at diagnosis showed a 46,XY,t(X;11)(p11.2;q23)[13]/46,XY[7] karyotype. Read More

View Article
December 2018

Megakaryocytic leukemia 1 (MKL1) mediates high glucose induced epithelial-mesenchymal transition by activating LOX transcription.

Biochem Biophys Res Commun 2018 Dec 13. Epub 2018 Dec 13.

Key Laboratory of Targeted Intervention of Cardiovascular Disease and Collaborative Innovation Center for Cardiovascular Translational Medicine, Department of Pathophysiology, Nanjing Medical University, Nanjing, China; Institute of Biomedical Research, Liaocheng University, Liaocheng, China. Electronic address:

Diabetic retinopathy (DR) is one of the most devastating complications of diabetes mellitus. When exposed to high glucose (HG), retinal epithelial cells undergo profound alterations both morphologically and functionally in a well-conserved process known as epithelial-to-mesenchymal transition (EMT). The mechanism governing HG-induced EMT in retinal epithelial cells is not completely understood. Read More

View Article
December 2018

Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

Leuk Res 2018 Nov 27;76:39-47. Epub 2018 Nov 27.

Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.

Flow-cytometric detection of now termed measurable residual disease (MRD) in acute myeloid leukemia (AML) has proven to have an independent prognostic impact. In a previous multicenter study we developed protocols to accurately define leukemia-associated immunophenotypes (LAIPs) at diagnosis. It has, however, not been demonstrated whether the use of the defined LAIPs in the same multicenter setting results in a high concordance between centers in MRD assessment. Read More

View Article
November 2018
1 Read

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.

Int J Pharm 2018 Dec 12. Epub 2018 Dec 12.

The Netherlands Cancer Institute, Division of Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address:

Quizartinib, a second-generation FLT3 inhibitor, is in clinical development for the treatment of acute myeloid leukemia. We studied its pharmacokinetic interactions with the multidrug efflux transporters ABCB1 and ABCG2 and the multidrug metabolizing enzyme CYP3A, using in vitro transport assays and knockout and transgenic mouse models. Quizartinib was transported by human ABCB1 in vitro, and by mouse (m)Abcb1 and mAbcg2 in vivo. Read More

View Article
December 2018

The role of SRC family kinases in FLT3 signaling.

Int J Biochem Cell Biol 2018 Dec 12. Epub 2018 Dec 12.

Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden; Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden; Division of Oncology, Skåne University Hospital, Lund, Sweden. Electronic address:

The receptor tyrosine kinase FLT3 is expressed almost exclusively in the hematopoietic compartment. Binding of its ligand, FLT3 ligand (FL), induces dimerization and activation of its intrinsic tyrosine kinase activity. This leads to autophosphorylation of FLT3 on several tyrosine residues which constitute high affinity binding sites for signal transduction molecules. Read More

View Article
December 2018
1 Read

DNA aptamers in detection of leukemia cells by thickness shear mode acoustics method.

Chemphyschem 2018 Dec 15. Epub 2018 Dec 15.

SLOVAKIA.

Using thickness shear mode acoustics method (TSM) and single molecule force spectroscopy (SMFS) we studied the interactions between DNA aptamers (sgc8c) specific to the protein tyrosine kinase 7 (PTK7) localized in the membranes of leukemia lymphoblastics (MOLT-4) and lymphocyte (Jurkat) cell lines as well with PTK7-free U266 myeloid leukemia cells. TSM method allowed development of high sensitive label-free biosensor for detection leukemia cells with limit of detection 195±20 cells/mL. SMFS approved high selectivity of sgc8c aptamers to the PTK7 receptors at the cell surface and allowed determination of binding probability of the aptamers to the PTK7 receptors at different cell lines. Read More

View Article
December 2018

BRD4 interacts with PML/RARα in acute promyelocytic leukemia.

Front Med 2018 Dec 14;12(6):726-734. Epub 2018 Dec 14.

State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Bromodomain-containing 4 (BRD4) has been considered as an important requirement for disease maintenance and an attractive therapeutic target for cancer therapy. This protein can be targeted by JQ1, a selective small-molecule inhibitor. However, few studies have investigated whether BRD4 influenced acute promyelocytic leukemia (APL), and whether BRD4 had interaction with promyelocytic leukemia-retinoic acid receptor α (PML/RARα) fusion protein to some extent. Read More

View Article
December 2018

Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.

Leukemia 2018 Dec 14. Epub 2018 Dec 14.

Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

Minimal residual disease (MRD) measured by PCR of clonal IgH/TCR rearrangements predicts relapse in T-cell acute lymphoblastic leukemia (T-ALL) and serves as risk stratification tool. Since 10% of patients have no suitable PCR-marker, we evaluated flowcytometry (FCM)-based MRD for risk stratification. We included 274 T-ALL patients treated in the NOPHO-ALL2008 protocol. Read More

View Article
December 2018

Refining AML outcome prediction.

Leukemia 2018 Dec 14. Epub 2018 Dec 14.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

View Article
December 2018

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.

Blood Adv 2018 Dec;2(24):3566-3571

Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.

Early data on venetoclax-containing regimens for the treatment of chronic lymphocytic leukemia (CLL) show promising results with deep remissions, but are hampered by potential risk for tumor lysis syndrome (TLS). Whether optimal duration of venetoclax treatment can be guided by minimal residual disease (MRD) is currently unknown. To study whether TLS risk can be mitigated in an unfit population by introducing preinduction, and whether MRD-guided duration of venetoclax treatment is a feasible and efficacious approach, we performed the Dutch-Belgian Cooperative Trial Group for Hemato-oncology (HOVON) 139/GIVE trial. Read More

View Article
December 2018

Transcription Factor Motif Density Can Confer Transcriptional Addiction.

Authors:

Cancer Discov 2018 Dec 14. Epub 2018 Dec 14.

ZFP64 binds to the promoter and is essential for the growth of -rearranged leukemia cells. Read More

View Article
December 2018

Implementing a comprehensive translational oncology platform: from molecular testing to actionability.

J Transl Med 2018 Dec 14;16(1):358. Epub 2018 Dec 14.

Oregon Health and Science University, 3181 SW Sam Jackson Hall, Portland, OR, 97239-3098, USA.

Background: In order to establish the workflows required to implement a real-time process involving multi-omic analysis of patient samples to support precision-guided therapeutic intervention, a tissue acquisition and analysis trial was implemented. This report describes our findings to date, including the frequency with which mutational testing led to precision-guided therapy and outcome for those patients.

Methods: Eligible patients presenting to Oregon Health and Science University Knight Cancer Institute were enrolled on the study. Read More

View Article
December 2018

A Lateral Neck Myeloid Sarcoma Presenting as Acute Otitis Externa.

Arch Iran Med 2018 Nov 1;21(11):544-546. Epub 2018 Nov 1.

Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences, Tehran, Iran.

Myeloid sarcoma (MS) is a solid extra-medullary tumor of immature myeloid cells which could occur before, during or after remission of acute leukemia at any site on the body. Owing to variation in differential diagnosis, pathologic evaluation and immunohistochemical staining are essential for definitive diagnosis. Rarely, MS has been shown as an isolated extramedullary relapse (iEMR) after allogeneic stem cell transplantation (allo-SCT), which often does not necessarily result in bone marrow involvement. Read More

View Article
November 2018

23-Hydroxyursolic Acid Isolated from the Stem Bark of Induces Apoptosis through Fas/Caspase-8-Dependent Pathway in HL-60 Human Promyelocytic Leukemia Cells.

Molecules 2018 Dec 13;23(12). Epub 2018 Dec 13.

Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea.

The natural product 23-hydroxyursolic acid (23-HUA) is a derivative of ursolic acid, which is known to induce cancer cell apoptosis. However, apoptotic effects and mechanisms of 23-HUA have not been well characterized yet. Herein, we investigated the molecular mechanisms of 23-HUA-induced apoptosis in HL-60 human promyelocytic leukemia cells. Read More

View Article
December 2018

Precision Medicine in Pediatric Cancer: Current Applications and Future Prospects.

High Throughput 2018 Dec 13;7(4). Epub 2018 Dec 13.

Departments of Pathology and Pediatric Hematology-Oncology, University of Missouri School of Medicine, Kansas City, MO 64108, USA.

Precision oncologic medicine is an emerging approach for cancer treatment that has recently taken giant steps in solid clinical practice. Recent advances in molecular diagnostics that can analyze the individual tumor's variability in genes have provided greater understanding and additional strategies to treat cancers. Although tumors can be tested by several molecular methods, the use of next-generation sequencing (NGS) has greatly facilitated our understanding of pediatric cancer and identified additional therapeutic opportunities. Read More

View Article
December 2018

ELK1-induced upregulation of long non-coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2.

Biomed Pharmacother 2019 Jan 5;109:788-797. Epub 2018 Nov 5.

Zhejiang Chinese Medical University, No.548 Bingwen road, Bingjiang district, Hangzhou, Zhejiang province, 310053, China. Electronic address:

Osteosarcoma (OS) is the commonest malignant bone tumor in the world. High incidence of OS has gradually become a social problem. Recent years, numerous studies have revealed that long non-coding RNAs (lncRNAs) are crucial regulators in the tumor progression. Read More

View Article
January 2019
1 Read

Molecular targeting for treatment of human T-lymphotropic virus type 1 infection.

Biomed Pharmacother 2019 Jan 5;109:770-778. Epub 2018 Nov 5.

Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

Human T-cell lymphotropic virus type 1 (HTLV-1) infection is linked to adult T-cell leukemia-lymphoma (ATLL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and several other disorders. ATLL occurs in approximately 5% of the 15-20 million people infected by HTLV-1 in the world. In general, ATLL is resistant to chemotherapy, which underlines the need for new and effective therapeutic strategies. Read More

View Article
January 2019
1 Read

The applications of anti-CD20 antibodies to treat various B cells disorders.

Biomed Pharmacother 2019 Jan 30;109:2415-2426. Epub 2018 Nov 30.

Department of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran.

B-lymphocyte antigen CD20 (called CD20) is known as an activated-glycosylated phosphoprotein which is expressed on the surface of all B-cells. CD20 is involved in the regulation of trans-membrane Ca conductance and also play critical roles in cell-cycle progression during human B cell proliferation and activation. The appearance of monoclonal antibody (mAb) technology provided an effective field for targeted therapy in treatment of a variety of diseases such as cancer, and autoimmune diseases. Read More

View Article
January 2019

The depletion of PHF6 decreases the drug sensitivity of T-cell acute lymphoblastic leukemia to prednisolone.

Biomed Pharmacother 2019 Jan 28;109:2210-2217. Epub 2018 Nov 28.

Department of Pediatric Hematology, Nanyang City Center Hospital, Nanyang, 473000, HeNan, China.

Mutation of PHF6 has been identified in Börjeson-Forssman-Lehmann syndrome and some types of subsets of childhood leukemia. However, the molecular function and the relationship of PHF6 mutation with glucocorticoid drug resistance during T-ALL treatment remains elusive. Here we report the influence of PHF6 expression on the drug response of T-ALL to prednisolone, and the underlying mechanism of this. Read More

View Article
January 2019

Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.

Biomed Pharmacother 2019 Jan 27;109:2173-2181. Epub 2018 Nov 27.

Institute of Biology and Ecology, Department of Cellular Biology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54 Košice, Slovakia. Electronic address:

Breast cancer resistance protein (BCRP) belongs to the family of ATP-binding cassette (ABC) transporters, overexpression of which can confer a multidrug-resistant phenotype in cancer cells and tumors. BCRP mediates efflux of numerous xenobiotics, including various chemotherapeutic agents and photosensitizers. Hypericin (HY) is a naturally-occurring photosensitizer synthesized by plants of the genus Hypericum. Read More

View Article
January 2019

Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro.

Biomed Pharmacother 2019 Jan 26;109:2084-2089. Epub 2018 Nov 26.

Department of Physiology, Guilin Medical University, Guilin 541004, PR China. Electronic address:

Many breast cancer patients suffer from obvious side effects induced by chemotherapy. Formononetin (FM), one kind ingredient of Chinese herbal medicine, has been suggested to inhibit MCF-7 breast cancer cells. And recently metformin (MET) has gained more attention as a potential anti-cancer drug. Read More

View Article
January 2019
1 Read

TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.

Biomed Pharmacother 2019 Jan 26;109:1793-1801. Epub 2018 Nov 26.

Pediatric Intensive Care Units, Shangqiu first People's Hospital, Shangqiu, 476100, China. Electronic address:

Increasing evidence has suggested the involvement of long non-coding RNA (lncRNA) taurine upregulated gene 1 (TUG1) in chemoresistance of cancer treatment. However, its function and molecular mechanisms in acute myeloid leukemia (AML) chemoresistance are still not well elucidated. In the present study, we investigate the functional role of TUG1 in Adriamycin (ADR) resistance of AML and discover the underlying molecular mechanism. Read More

View Article
January 2019
1 Read

TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway.

Biomed Pharmacother 2019 Jan 16;109:1640-1649. Epub 2018 Nov 16.

Department of Pediatric Internal Medicine, Cangzhou Central Hospital, Xihuan Middle Street, Yunhe District, Cangzhou city, Hebei Province 061000, China.

Acute lymphoblastic leukemia (ALL) is characterized by abnormal lymphoblasts accumulation in the bone marrow and blood. Despite great efforts have been made in exploring novel therapeutic method, the prognosis of children with ALL is still unsatisfied. Glucocorticoid (GC) resistance is a great obstacle for the clinical treatment of ALL. Read More

View Article
January 2019
1 Read

Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

J Natl Cancer Inst 2018 Dec 14. Epub 2018 Dec 14.

University of California San Diego School of Medicine, UCSD School of Medicine, La Jolla, CA.

Background: Chimeric antigen receptor T-cell (CAR-T) therapy is a promising new class of cancer therapy but has a high up-front cost. We evaluated the cost-effectiveness of CAR-T therapy among pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).

Methods: We built a microsimulation model for pediatric patients with relapsed/refractory B-ALL receiving either CAR-T therapy or standard of care. Read More

View Article
December 2018
1 Read

Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-κB/COX-2 signaling pathways.

Cancer Lett 2018 Dec 10. Epub 2018 Dec 10.

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China; State Key Laboratory of Targeted Drug for Tumors of Guangdong Province, Guangzhou Double Bioproduct Inc., Guangzhou, China. Electronic address:

MLL-rearranged leukemia is an aggressive malignancy associated with poor outcome, which is refractory to conventional treatment. Melatonin has been proven to exert anti-tumor activity, but the effect of melatonin on MLL-r leukemia and the underlying mechanism remain poorly understood. In this study, melatonin inhibited cell proliferation and induced apoptosis by activating the caspase-dependent apoptotic pathway in MLL-r leukemia cells. Read More

View Article
December 2018
1 Read

Expression of CD25 fluctuates in the leukemia-initiating cell population of CD25-positive AML.

PLoS One 2018 14;13(12):e0209295. Epub 2018 Dec 14.

Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.

CD25 is expressed on leukemic cells in 10-20% cases of acute myeloid leukemia (AML), and its expression is associated with poor prognosis. We reevaluated the relationship between CD25 expression and the leukemia-initiating cell (LIC) properties of AML using a patient-derived xenograft model. We divided lineage marker-negative (Lin-) CD34+CD38- or Lin-CD34+ cells from CD25-positive AML into CD25-positive and -negative populations, and then transplanted each population into NOD. Read More

View Article
December 2018
1 Read

Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study.

J Pediatr Hematol Oncol 2019 Jan;41(1):e12-e17

Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus.

Background: As more children survive acute myeloid leukemia (AML) it is increasingly important to assess possible late effects of the intensive treatment. Hearing loss has only sporadically been reported in survivors of childhood AML. We assessed hearing status in survivors of childhood AML treated with chemotherapy alone according to 3 consecutive NOPHO-AML trials. Read More

View Article
January 2019

The current role of clinical flow cytometry in the evaluation of mature B-cell neoplasms.

Cytometry B Clin Cytom 2018 Dec 13. Epub 2018 Dec 13.

Mayo Clinic Arizona, Phoenix, Arizona.

Flow cytometry (FC) has a well-established role in the diagnostic evaluation of mature B-cell neoplasms. Effective assessment for lineage associated antigens, aberrant antigen expression, and immunoglobulin light chain restriction requires a well-designed, optimized, and controlled FC assay. However, it is important for hematopathologists to know when flow cytometry has a more limited role, and other modalities, such as immunohistochemistry, cytogenetic and molecular testing, are more important. Read More

View Article
December 2018
1 Read

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.

Br J Haematol 2018 Dec 13. Epub 2018 Dec 13.

Service d'Hématologie Clinique, Hôpital St. Louis and Paris 7 University, Paris, France.

Many patients with lower-risk myelodysplastic syndrome (MDS) experience anaemia, which has negative consequences. Erythropoiesis-stimulating agents (ESAs) and their biosimilars are used to treat anaemia in MDS and, currently, epoetin alfa and darbepoetin alfa are commonly used and recommended by clinical guidelines. To better understand the evidence available on the use of ESAs for anaemia in lower-risk MDS, we conducted a systematic literature review to identify randomized and nonrandomized prospective studies reporting on clinical efficacy/effectiveness, patient-reported quality of life (QoL), and safety. Read More

View Article
December 2018

Prevention of mercaptopurine-induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites.

Pediatr Blood Cancer 2018 Dec 13:e27577. Epub 2018 Dec 13.

Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.

Skewing of mercaptopurine (6-MP) metabolism preferentially toward the 6-methylmercaptopurine (6-MMP) metabolite over the antileukemic metabolite 6-thioguanine (6-TGN) is associated with 6-MP-related hepatotoxocity. Allopurinol when coadministered with 6-MP can reduce this skewing and ameliorate the associated adverse effects. The cases we report here demonstrate that aberrant overproduction of 6-MMP is also associated with profound 6-MP-associated hypoglycemia, which can be reversed by administration of allopurinol. Read More

View Article
December 2018

Cutaneous mucormycosis.

Transpl Infect Dis 2018 Dec 13:e13039. Epub 2018 Dec 13.

Department of Hematology, AZ Delta Roeselare.

Mucormycosis is an aggressive invasive fungal infection that occurs rarely in immunocompetent but frequently in immunocompromised patients. We present a case of a 68-year old patient with cutaneous mucormycosis due to Rhizopus pusillus. He was initially hospitalized for invasive pulmonary aspergillosis and diabetes mellitus secondary to acute graft-versus-host treatment with glucocorticoids after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Read More

View Article
December 2018

Targeting of mTORC1/2 by dihydroevocarpine induces cytotoxicity in acute myeloid leukemia.

J Cell Physiol 2018 Dec 12. Epub 2018 Dec 12.

Department of Pathology, Huaiyin Hospital of Huai'an city, Huai'an, China.

Interactions between the tumor cells and bone marrow (BM) microenvironment promote survival, growth, and chemoresistance of acute myeloid leukemia (AML). The mTOR pathway plays a key role in mediating the AML-BM microenvironment interactions. Here, we report the anti-AML activity of a natural monomer extracted from the Chinese medicinal herb Evodia rutaecarpa, dihydroevocarpine. Read More

View Article
December 2018
3.839 Impact Factor

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.

Br J Haematol 2018 Dec 13. Epub 2018 Dec 13.

Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Delayed lymphocyte and T-cell immune reconstitution following bendamustine-rituximab (BR) for indolent non-Hodgkin lymphoma (iNHL) has been described, but no information is available for chronic lymphocytic leukaemia (CLL). We present a population-based retrospective analysis of immune reconstitution and risk of infection following BR. Outcomes included timing/correlates of CD4+ recovery and risk of ≥grade 3 infections. Read More

View Article
December 2018

Cancer risk among children conceived by fertility treatment.

Int J Cancer 2018 Dec 13. Epub 2018 Dec 13.

Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Hunan, China.

Prior studies on the association between fertility treatment and childhood cancer risk have generated inconsistent results. We performed a systematic review and meta-analysis of observation studies to summarize the evidence regarding the relation of fertility treatment with childhood cancer risk. A systematic literature search of several databases was conducted through April 2018 to identify relevant studies. Read More

View Article
December 2018
1 Read

Abnormal Morphological and Functional Nature of Bone Marrow Stromal Cells Provides Preferential Support for Survival of Acute Myeloid Leukemia Cells.

Int J Cancer 2018 Dec 13. Epub 2018 Dec 13.

Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.

Hematopoietic progenitors, residing in the bone marrow (BM) niche, are supported by mesenchymal stromal cells (MSCs). Cytogenetic and molecular aberrations in these progenitors lead to acute myeloid leukemia (AML). The BM-MSC role in leukemogenesis is not fully elucidated. Read More

View Article
December 2018
1 Read

Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.

Cancer 2018 Dec 12. Epub 2018 Dec 12.

Department of Public Health Sciences, The University of Chicago, Chicago, Illinois.

Background: Granulocyte colony-stimulating factors (G-CSFs), which are used for the prevention of complications from chemotherapy-related neutropenia, are linked to the risk of developing second primary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The objective of this study was to examine the correlation between using a specific G-CSF agent and the risk of MDS/AML among older patients with non-Hodgkin lymphoma (NHL).

Methods: This was a retrospective cohort study of adults aged >65 years who were diagnosed with first primary NHL between 2001 and 2011. Read More

View Article
December 2018

Potent anti-proliferative effect of fatty-acid derivative AIC-47 on leukemic mice harboring BCR-ABL mutation.

Cancer Sci 2018 Dec 12. Epub 2018 Dec 12.

United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.

Therapy based on targeted inhibition of BCR-ABL tyrosine kinase has greatly improved the prognosis for patients with Philadelphia chromosome (Ph)-positive leukemia and tyrosine kinase inhibitors (TKIs) have become the standard therapy. However, some patients acquire resistance to TKIs that is frequently associated with point mutations in the BCR-ABL. We previously reported that a medium-chain fatty-acid derivative AIC-47 induced transcriptional suppression of BCR-ABL and perturbation of the Warburg effect, leading to growth inhibition in Ph-positive leukemia cells. Read More

View Article
December 2018

Overexpression of Hes1 is involved in sensitization of K562 cells to Imatinib.

J Cell Biochem 2018 Dec 11. Epub 2018 Dec 11.

Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.

Tyrosine kinase inhibitor (TKI)-based therapy has created promising results among much chronic myeloid leukemia (CML) patients. Imatinib as a relatively specific inhibitor of Bcr-Abl is at present one of the undisputed therapeutic agent for newlydiagnosed patients with CML. However, the occurrence of imatinib-resistance enlightens the urgent need to identify other therapeutic agents against CML. Read More

View Article
December 2018

Cause-specific mortality among medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

Cancer 2018 Dec 11. Epub 2018 Dec 11.

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Background: As the US population ages and non-Hodgkin lymphoma (NHL)-specific mortality declines, deaths from causes other than NHL will become increasingly important in treatment decision making for older patients with NHL. The objective of the current study was to describe how the 5-year cumulative incidence of NHL-specific and other-cause mortality varies by subtype, age, comorbidity level, and time since diagnosis in older patients.

Methods: Using the Surveillance, Epidemiology, and End Results cancer registry data linked to Medicare claims, patients aged ≥66 years were identified at the time of diagnosis with a first, primary NHL diagnosis from 2004 through 2013. Read More

View Article
December 2018

Molecular characterization of a MLL1 fusion and its role in chromosomal instability.

Mol Oncol 2018 Dec 8. Epub 2018 Dec 8.

Department of Pathology and Laboratory Medicine, Cancer Cluster, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 5E5, Canada.

Chromosomal rearrangements involving the mixed-lineage leukemia (MLL1) gene are common in a unique group of acute leukemias, with more than 100 fusion partners in this malignancy alone. However, do these fusions occur or have a role in solid tumors? We performed extensive network analyses of MLL1-fusion partners in patient datasets, revealing that multiple MLL1-fusion partners exhibited significant interactions with the androgen-receptor signaling pathway. Further exploration of tumor sequence data from TCGA predicts the presence of MLL1 fusions with truncated SET domain in prostate tumors. Read More

View Article
December 2018

Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are Developed.

AIDS Rev 2018 ;20(4):220-225

Department of Neuroscience, Center for Translational AIDS Research, Philadelphia, USA.

Here, we review the progress that has been made in achieving a cure of HIV-1 infection. To date, this has only occurred in one person after he received allogeneic stem cell transplants from a CCR5 ∆32 homozygous donor in addition to chemotherapy and radiation to treat his acute myelocytic leukemia. The general consensus is that achieving a sustained remission of infection in the absence of antiretroviral therapy will involve a combination of strategies that involve both the targeting of the latent proviral genome and the induction of more effective anti-HIV-1 immune responses. Read More

View Article
January 2018
1 Read

MISC: missing imputation for single-cell RNA sequencing data.

BMC Syst Biol 2018 Dec 14;12(Suppl 7):114. Epub 2018 Dec 14.

Joint Bioinformatics Program, University of Arkansas Little Rock George Washington Donaghey College of Engineering & IT and University of Arkansas for Medical Sciences, Little Rock, AR, 72204, USA.

Background: Single-cell RNA sequencing (scRNA-seq) technology provides an effective way to study cell heterogeneity. However, due to the low capture efficiency and stochastic gene expression, scRNA-seq data often contains a high percentage of missing values. It has been showed that the missing rate can reach approximately 30% even after noise reduction. Read More

View Article
December 2018